Latest Brazil news and updates from Switzerland. AI-curated articles covering Brazil topics.
Swiss pharmaceutical firm Sandoz has received marketing authorization in Brazil for a generic version of the popular GLP-1 drug semaglutide. The move marks a significant expansion for the Basel-based company into the lucrative $1.8 billion Brazilian market for diabetes treatments.
From trusted Swiss news outlets